The present disclosure generally relates to detection of crystallinity, and in particular to a method and apparatus for rapid detection of homochiral crystallinity particularly in pharmaceutical formulations.
This section introduces aspects that may help facilitate a better understanding of the disclosure. Accordingly, these statements are to be read in this light and are not to be understood as admissions about what is or is not prior art.
The chemical complexity of emerging drug molecules is rapidly increasing. This complexity is driven by the desire for more potent drugs with higher specificity and fewer side effects, and presents growing challenges in formulation design for ensuring bioavailability. Active pharmaceutical ingredients (APIs) and new chemical entities are typically required to be sufficiently hydrophobic to pass through cell membranes to enter the bloodstream and reach their targets. However, that hydrophobicity must be balanced by a sufficiently high aqueous solubility. As the size and complexity of the API increases, these mutually exclusive properties become increasingly difficult to simultaneously satisfy. Approximately 70-90% of potential API candidates suffer from poor aqueous solubility (BCS class II and IV). The added cost in the identification and characterization of abandoned candidates could easily reach into the hundreds of millions of dollars annually, industry wide.
Amorphous solid dispersions (ASDs) are an attractive option for increasing the bioavailability of APIs through the development of formulations containing higher free energy solid state forms, with correspondingly faster dissolution rates. However, the higher free energy comes at a price; ASDs are typically metastable with the potential to crystallize over widely varying timescales. Accordingly, accelerated stability studies in which an amorphous formulation is subjected to increased temperature and relative humidity remain the gold standard for characterizing long-term stability of an ASD. Such studies often require several months of exposure to harsh conditions before crystallinity is present at a level amenable to reliable quantitation. The time cost associated with accelerated stability studies produces a major bottleneck in the drug formulations pipeline.
The most widespread current approaches used for assessing crystallinity in APIs and API formulations include X-ray powder diffraction (PXRD), spectrochemical techniques including Raman, differential scanning calorimetry (DSC), solid state NMR (ssNMR), and scanning electron microscopy (SEM). Unfortunately, the detection limits for most of these techniques under normal conditions are on the order of 1-5% crystallinity, proving problematic for detecting trace crystallinity, particularly in formulations with low (˜5-10%) drug loadings as is becoming commonplace in modern pharmaceuticals. Second harmonic generation microscopy (SHG) has been used to rapidly detect and quantify trace crystallinity in amorphous formulations, showing detection limits in the sub-ppm regime. Unfortunately, the instrument costs associated with SHG create a practical barrier to ubiquitous implementation, restricting its use to a relatively small subset of well-funded and well-staffed facilities. There is therefore an unmet need for robust and compact measurement tools compatible with process analytical technology applications capable of identifying trace crystallinity within solid-state formulations.
According to one aspect of the present disclosure, an apparatus is provided, comprising a sample holder for holding a sample, the sample holder having at least one optically transparent plate and a covering member for securing the sample between the covering member and the transparent plate, wherein the sample is between and in mechanical contact with the transparent plate and the covering member, a kinetic energy director configured to deliver kinetic energy impulses to the sample through the sample holder to induce triboluminescence of the sample, and a light detection unit configured to detect luminescence from the sample and output a signal representative of the level of luminescence. The apparatus may include a recording device to record a temporal response of the light detection unit and a trigger device which senses an impact event on the sample and outputs a trigger signal to the recording device. A timing controller may also be included, the timing controller a operatively connected to the kinetic energy director and the recording device, the timing controller configured to synchronize actuation of the kinetic energy director and the recording device to cause the recording device to capture the output signal of the light detection unit when the kinetic energy director strikes the sample holder.
According to another aspect, an apparatus is provided, comprising a sample holder for holding a sample, the sample holding having at least one cavity for containing a liquid sample, an acoustic transducer configured to direct sonic energy impulses to the sample to induce sonotriboluminescence of the sample, and a light detection unit configured to detect luminescence from the sample and output a signal representative of the level of luminescence. The apparatus may include a recording device to record a temporal response of the light detection unit and a trigger device which senses an impact event on the sample and outputs a trigger signal to the recording device. A timing controller may also be included, the timing controller a operatively connected to the kinetic energy director and the recording device, the timing controller configured to synchronize actuation of the kinetic energy director and the recording device to cause the recording device to capture the output signal of the light detection unit when the kinetic energy director strikes the sample holder.
The above and other objects, features, and advantages of the present invention will become more apparent when taken in conjunction with the following description and drawings wherein identical reference numerals have been used, where possible, to designate identical features that are common to the figures, and wherein:
For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to the embodiments illustrated in the drawings, and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of this disclosure is thereby intended.
Presented herein impact-driven triboluminescence of homochrial API crystals as a novel measurement tool for rapidly assessing the presence of trace crystallinity within nominally amorphous pharmaceutical powders. According to one aspect, the disclosed measurement apparatus has the advantage of providing accurate measurement using a simple device with correspondingly low materials costs.
Triboluminescence is a phenomenon in which mechanical action results in emission of optical radiation. Bright triboluminescence arises when the mechanic perturbation couples to electric field generation due to piezoelectricity, which can then result in light emission, either by dielectric breakdown or through energy transfer to fluorophores. Based on this mechanism, efficient triboluminescence is expected in crystals that are both piezoelectrically active and are capable of supporting fluorescence.
Crystals of homochiral molecules are constructed from noncentrosymmetric building blocks, and therefore must adopt noncentrosymmetric lattices. Noncentrosymmetry is also a requirement for piezoelectricity, such that the overwhelming majority of chiral crystals fall into space groups that are piezoelectrically active. Furthermore, approximately 75% of new small molecule drug candidates contain aromatic groups that can support ultraviolet fluorescence. The presently disclosed apparatus and method utilize triboluminescence for fast and simple identification of trace crystallinity within otherwise amorphous materials.
In operation, kinetic energy impulses are delivered to the sample holder 104, mechanically compressing the sample 110 between the plates 116 and 118 to induce triboluminescence. Light emitted by the sample 110 is then collimated by the lens 112, redirected 90 degrees by a mirror 113, and then collected and focused onto the PMT 108 by lens 114. The PMT 108 outputs a voltage signal which corresponds to the level of light entering the PMT 108. In certain embodiments, the PMT 108 output is connected to a recording device 124. The recording device 124 may comprise an oscilloscope. An example of a suitable oscilloscope is the Tektronix Model TDS 3054B. Digital oscilloscopes may be as the recording device and further connected to a computing device for further recording, analysis, and processing of the data received from the detector 108. The recording device 124 records the temporal response of the luminescence from the sample 110. In certain embodiments, a trigger unit 122 is included which is mechanically connected to the sample holder by a member 120 and a support structure 121. The trigger unit may comprise a piezoelectric transducer, such as a lead zirconate titanate (PZT) ceramic piezoelectric transducer. The oscilloscope 124 is triggered by the trigger unit 122 based on detection of an acoustic wave produced upon impact of the sample. The trigger unit 122 may reduce noise by gating the detection to the moment of sample impact and signal generation. To minimize background, the PMT 108 and the sample holder 104 are physically separated from each other by an air gap. This design of the plates 116 and 118 allows the kinetic energy to be transferred evenly across the sample 110, while reducing the risk of transfer of material to the mechanical impulse generator (e.g., brass ball). The kinetic energy impulse in the embodiment of
In addition, still referring to
The apparatus of
In
Those skilled in the art will recognize that numerous modifications can be made to the specific implementations described above. The implementations should not be limited to the particular limitations described. Other implementations may be possible.
The present U.S. patent application is related to and claims the priority benefit of U.S. Provisional Patent Application Ser. No. 62/233,391, filed Sep. 27, 2015, the contents of which are hereby incorporated by reference in their entirety into the present disclosure.
This invention was made with government support under 1412888 awarded by the National Science Foundation. The government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US16/54030 | 9/27/2016 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62233391 | Sep 2015 | US |